Cells, cytokines and inflammatory bowel disease: A clinical perspective

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 6, 2011, Pages 703-716

  Roberts Thomson, Ian C ^a   Fon, James ^a   Uylaki, Wendy ^a   Cummins, Adrian G ^a   Barry, Simon ^a  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

Crohn's disease; cytokines; inflammatory cells; pathogenesis of disease; ulcerative colitis

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CD14 ANTIGEN; CD2 ANTIGEN; CD209 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; CYTOKINE; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; PHOSPHOLIPASE A2; PROTEIN KINASE C; SELECTIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL SUBPOPULATION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CROHN DISEASE; CYTOKINE PRODUCTION; DENDRITIC CELL; EOSINOPHIL; EPITHELIUM CELL; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; INTESTINE MUCOSA; MACROPHAGE ACTIVATION; MAST CELL; NATURAL KILLER CELL; NEUTROPHIL; PATHOGENESIS; PHAGOCYTE; PLASMA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; TH1 CELL; TH2 CELL; ULCERATIVE COLITIS; UPREGULATION;

CD4-POSITIVE T-LYMPHOCYTES; COLITIS, ULCERATIVE; CROHN DISEASE; CYTOKINES; HUMANS; KILLER CELLS, NATURAL; MACROPHAGES; NEUTROPHILS;

EID: 80155182156     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.11.74     Document Type: Review

References (102)

1. Fujimura Y, Kamoi R, Iida M. Pathogenesis of aphthoid ulcers in Crohn's disease: correlative findings by magnifying colonoscopy, electron microscopy, and immunohistochemistry. Gut 38(5), 724-732 (1996).
2. Kakazu T, Hara J, Matsumoto T et al. Type 1 T-helper cell predominance in granulomas of Crohn's disease. Am. J. Gastroenterol. 94(8), 2149-2155 (1999).
3. Surawicz CM, Belic L. Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease. Gastroenterology 86(1), 104-113 (1984).
4. Allison MC, Hamilton-Dutoit SJ, Dhillon AP, Pounder RE. The value of rectal biopsy in distinguishing self-limited colitis from early inflammatory bowel disease. Q. J. Med. 65(248), 985-995 (1987).
5. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124(4), 823-835 (2006).
6. Serhan CN, Brain SD, Buckley CD et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21(2), 325-332 (2007).
7. Barton GM. A calculated response: control of inflammation by the innate immune system. J. Clin. Invest. 118(2), 413-420 (2008).
8. Medzhitov R. Origin and physiological roles of inflammation. Nature 454(7203), 428-435 (2008).
9. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8(5), 349-361 (2008).
10. Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat. Immunol. 12(1), 5-9 (2011).
11. Hanai H, Takeuchi K, Iida T et al. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig. Dis. Sci. 49(9), 1438-1443 (2004).
12. Arnott ID, Drummond HE, Ghosh S. Gut luminal neutrophil migration is influenced by the anatomical site of Crohn's disease. Eur. J. Gastroenterol. Hepatol. 13(3), 239-243 (2001).
13. Anezaki K, Asakura H, Honma T et al. Correlations between interleukin-8, and myeloperoxidase or luminol-dependent chemiluminescence in inflamed mucosa of ulcerative colitis. Intern. Med. 37(3), 253-258 (1998).
14. Mccarthy DA, Rampton DS, Liu YC. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin. Exp. Immunol. 86(3), 489-493 (1991).
15. Nikolaus S, Bauditz J, Gionchetti P, Witt C, Lochs H, Schreiber S. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 42(4), 470-476 (1998).
16. Carlson M, Raab Y, Seveus L, Xu S, Hallgren R, Venge P. Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis. Gut 50(4), 501-506 (2002).
17. Marks DJ, Harbord MW, Macallister R et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 367(9511), 668-678 (2006).
18. Stathaki MI, Koukouraki SI, Karkavitsas NS, Koutroubakis IE. Role of scintigraphy in inflammatory bowel disease. World J. Gastroenterol. 15(22), 2693-2700 (2009).
19. Naito Y, Takagi T, Yoshikawa T. Molecular fingerprints of neutrophil-dependent oxidative stress in inflammatory bowel disease. J. Gastroenterol. 42(10), 787-798 (2007).
20. Smith AM, Rahman FZ, Hayee BH et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J. Exp. Med. 206, 1883-1897 (2009).
21. Rahman FZ, Marks DJ, Hayee BH, Smith AM, Bloom SL, Segal AW. Phagocyte dysfunction and inflammatory bowel disease. Inflamm. Bowel Dis. 14(10), 1443-1452 (2008).
22. Sheikh SZ, Plevy SE. The role of the macrophage in sentinel responses in intestinal immunity. Curr. Opin. Gastroenterol. 26(6), 578-582 (2010).
23. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8(12), 958-969 (2008).
24. Huett A, Goel G, Xavier RJ. A systems biology viewpoint on autophagy in health and disease. Curr. Opin. Gastroenterol. 26(4), 302-309 (2010).
25. Kamada N, Hisamatsu T, Okamoto S et al. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-g axis. J. Clin. Invest. 118(6), 2269-2280 (2008).
26. + macrophages in intestinal lamina propria exhibit potent antigen-presenting ability. J. Immunol. 183(3), 1724-1731 (2009).
27. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 20, 495-549 (2002).
28. Becker C, Wirtz S, Neurath MF. Stepwise regulation of TH1 responses in autoimmunity: IL-12-related cytokines and their receptors. Inflamm. Bowel Dis. 11(8), 755-764 (2005).
29. Fantini MC, Monteleone G, Macdonald TT. New players in the cytokine orchestra of inflammatory bowel disease. Inflamm. Bowel Dis. 13(11), 1419-1423 (2007).
30. Himmel ME, Hardenberg G, Piccirillo CA, Steiner TS, Levings MK. The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology 125(2), 145-153 (2008).
31. Awasthi A, Murugaiyan G, Kuchroo VK. Interplay between effector Th17 and regulatory T cells. J. Clin. Immunol. 28(6), 660-670 (2008).
32. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu. Rev. Immunol. 27, 485-517 (2009).
33. + regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J. Clin. Immunol. 30(1), 80-89 (2009).
34. Hovhannisyan Z, Treatman J, Littman DR, Mayer L. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 140, 957-965 (2011).
35. Brandtzaeg P, Carlsen HS, Halstensen TS. The B-cell system in inflammatory bowel disease. Adv. Exp. Med. Biol. 579, 149-167 (2006).
36. Rescigno M. Intestinal dendritic cells. Adv. Immunol. 107, 109-138 (2010).
37. Kaser A, Ludwiczek O, Holzmann S et al. Increased expression of CCL20 in human inflammatory bowel disease. J. Clin. Immunol. 24(1), 74-85 (2004).
38. Baumgart DC, Metzke D, Schmitz J et al. Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells. Gut 54(2), 228-236 (2005).
39. Hart AL, Al-Hassi HO, Rigby RJ et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 129(1), 50-65 (2005).
40. Sakuraba A, Sato T, Kamada N, Kitazume M, Sugita A, Hibi T. Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. Gastroenterology 137(5), 1736-1745 (2009).
41. Sarin SK, Malhotra V, Sen Gupta S, Karol A, Gaur SK, Anand BS. Significance of eosinophil and mast cell counts in rectal mucosa in ulcerative colitis. A prospective controlled study. Dig. Dis. Sci. 32(4), 363-367 (1987).
42. Carvalho AT, Elia CC, De Souza HS et al. Immunohistochemical study of intestinal eosinophils in inflammatory bowel disease. J. Clin. Gastroenterol. 36(2), 120-125 (2003).
43. Lampinen M, Backman M, Winqvist O et al. Different regulation of eosinophil activity in Crohn's disease compared with ulcerative colitis. J. Leukoc. Biol. 84(6), 1392-1399 (2008).
44. Coppi LC, Thomazzi SM, Ayrizono MD et al. Comparative study of eosinophil chemotaxis, adhesion, and degranulation in vitro in ulcerative colitis and Crohn's disease. Inflamm. Bowel Dis. 13 (2), 211-218 (2006).
45. Raithel M, Winterkamp S, Pacurar A, Ulrich P, Hochberger J, Hahn EG. Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease. Scand. J. Gastroenterol. 36(2), 174-179 (2001).
46. Sokol H, Polin V, Lavergne-Slove A et al. Plexitis as a predictive factor of early postoperative clinical recurrence in Crohn's disease. Gut 58(9), 1218-1225 (2009).
47. + natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology 139(3), 882-892 (2010).
48. Fuss IJ, Heller F, Boirivant M et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113(10), 1490-1497 (2004).
49. Grose RH, Cummins AG, Thompson FM. Deficiency of invariant natural killer T cells in coeliac disease. Gut 56(6), 790-795 (2007).
50. Roda G, Sartini A, Zambon E et al. Intestinal epithelial cells in inflammatory bowel diseases. World J. Gastroenterol. 16(34), 4264-4271 (2010).
51. + regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J. Immunol. 174(9), 5814-5822 (2005).
52. Al-Sadi R, Boivin M, Ma T. Mechanism of cytokine modulation of epithelial tight junction barrier. Front Biosci. 14, 2765-2778 (2009).
53. Cario E. Heads up! How the intestinal epithelium safeguards mucosal barrier immunity through the inflammasome and beyond. Curr. Opin. Gastroenterol. 26(6), 583-590 (2010).
54. Bradley JR. TNF-mediated inflammatory disease. J. Pathol. 214(2), 149-160 (2008).
55. Murch SH, Braegger CP, Walker-Smith JA, Macdonald TT. Location of tumour necrosis factor a by immunohistochemistry in chronic inflammatory bowel disease. Gut 34(12), 1705-1709 (1993).
56. Macdonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumour necrosis factor- a and interferon-g production measured at the single cell level in normal and inflamed human intestine. Clin. Exp. Immunol. 81(2), 301-305 (1990).
57. Leon AJ, Gomez E, Garrote JA et al. High levels of proinflammatory cytokines, but not markers of tissue injury, in unaffected intestinal areas from patients with IBD. Mediators Inflamm. 2009, 580450 (2009).
58. Braegger CP, Nicholls S, Murch SH, Stephens S, Macdonald TT. Tumour necrosis factor a in stool as a marker of intestinal inflammation. Lancet 339(8785), 89-91 (1992).
59. Ghosh S, Chaudhary R, Carpani M, Playford R. Interfering with interferons in inflammatory bowel disease. Gut 55(8), 1071-1073 (2006).
60. Camoglio L, Te Velde AA, Tigges AJ, Das PK, Van Deventer SJ. Altered expression of interferon-g and interleukin-4 in inflammatory bowel disease. Inflamm. Bowel Dis. 4(4), 285-290 (1998).
61. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-g, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157(3), 1261-1270 (1996).
62. Gotteland M, Lopez M, Munoz C et al. Local and systemic liberation of proinflammatory cytokines in ulcerative colitis. Dig. Dis. Sci. 44(4), 830-835 (1999).
63. Reinisch W, Hommes DW, Van Assche G et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon g antibody, in patients with moderate to severe Crohn's disease. Gut 55(8), 1138-1144 (2006).
64. Raddatz D, Bockemuhl M, Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur. J. Gastroenterol. Hepatol. 17(5), 547-557 (2005).
65. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J. Gastroenterol. 14(27), 4280-4288 (2008).
66. Karttunnen R, Breese EJ, Walker-Smith JA, Macdonald TT. Decreased mucosal interleukin-4 (IL-4) production in gut inflammation. J. Clin. Pathol. 47(11), 1015-1018 (1994).
67. Mudter J, Neurath MF. Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm. Bowel Dis. 13(8), 1016-1023 (2007).
68. Van Kemseke C, Belaiche J, Louis E. Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission. Int. J. Colorectal Dis. 15(4), 206-210 (2000).
69. Ito H, Takazoe M, Fukuda Y et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126(4), 989-996 (2004).
70. Glocker EO, Kotlarz D, Boztug K et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361(21), 2033-2045 (2009).
71. Sabat R. IL-10 family of cytokines. Cytokine Growth Factor Rev. 21(5), 315-324 (2010).
72. Melgar S, Yeung MM, Bas A et al. Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin. Exp. Immunol. 134(1), 127-137 (2003).
73. Gasche C, Bakos S, Dejaco C, Tillinger W, Zakeri S, Reinisch W. IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease. J. Clin. Immunol. 20(5), 362-370 (2000).
74. Schreiber S, Fedorak RN, Nielsen OH et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's disease IL-10 cooperative study group. Gastroenterology 119(6), 1461-1472 (2000).
75. Sandborn WJ, Feagan BG, Fedorak RN et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135(4), 1130-1141 (2008).
76. Vainer B, Nielsen OH, Hendel J, Horn T, Kirman I. Colonic expression and synthesis of interleukin 13 and interleukin 15 in inflammatory bowel disease. Cytokine 12(10), 1531-1536 (2000).
77. Heller F, Florian P, Bojarski C et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129(2), 550-564 (2005).
78. Mannon PJ, Hornung RL, Yang Z et al. Suppression of inflammation in ulcerative colitis by interferon-b-1a is accompanied by inhibition of IL-13 production. Gut 60(4), 449-455 (2011).
79. Monteleone I, Pallone F, Monteleone G. Interleukin-23 and Th17 cells in the control of gut inflammation. Mediators Inflamm. 2009, 297645 (2009).
80. Fujino S, Andoh A, Bamba S et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52(1), 65-70 (2003).
81. Bogaert S, Laukens D, Peeters H et al. Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease. BMC Immunol. 11, 61 (2010).
82. Koenders MI, Van Den Berg WB. Translational mini-review series on Th17 cells: are T helper 17 cells really pathogenic in autoimmunity? Clin. Exp. Immunol. 159(2), 131-136 (2009).
83. D'acquisto F, Maione F, Pederzoli-Ribeil M. From IL-15 to IL-33: the never-ending list of new players in inflammation. Is it time to forget the humble aspirin and move ahead? Biochem. Pharmacol. 79(4), 525-534 (2010).
84. Maloy KJ. The Interleukin-23/ Interleukin-17 axis in intestinal inflammation. J. Intern. Med. 263(6), 584-590 (2008).
85. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314(5804), 1461-1463 (2006).
86. Maynard CL, Weaver CT. Immunology: context is key in the gut. Nature 471(7337), 169-170 (2011).
87. Olsen T, Goll R, Cui G et al. Tissue levels of tumor necrosis factor-a correlates with grade of inflammation in untreated ulcerative colitis. Scand. J. Gastroenterol. 42(11), 1312-1320 (2007).
88. Matsuda R, Koide T, Tokoro C et al. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naive ulcerative colitis during active and quiescent disease. Inflamm. Bowel Dis. 15(3), 328-334 (2009).
89. Pang YH, Zheng CQ, Yang XZ, Zhang WJ. Increased expression and activation of IL-12-induced Stat4 signaling in the mucosa of ulcerative colitis patients. Cell Immunol. 248(2), 115-120 (2007).
90. Inoue S, Matsumoto T, Iida M et al. Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity. Am. J. Gastroenterol. 94(9), 2441-2446 (1999).
91. Veny M, Esteller M, Ricart E, Pique JM, Panes J, Salas A. Late Crohn's disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients. Aliment. Pharmacol. Ther. 31(5), 561-572 (2009).
92. Ruffolo C, Scarpa M, Faggian D et al. Cytokine network in rectal mucosa in perianal Crohn's disease: relations with inflammatory parameters and need for surgery. Inflamm. Bowel Dis. 14(10), 1406-1412 (2008).
93. Seiderer J, Elben I, Diegelmann J et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm. Bowel Dis. 14(4), 437-445 (2008).
94. Sugihara T, Kobori A, Imaeda H et al. The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease. Clin. Exp. Immunol. 160(3), 386-393 (2010).
95. Schmidt C, Giese T, Ludwig B et al. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm. Bowel Dis. 11(1), 16-23 (2005).
96. Komatsu M, Kobayashi D, Saito K et al. Tumor necrosis factor-a in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno- PCR. Clin. Chem. 47(7), 1297-1301 (2001).
97. Ebert EC, Panja A, Das KM et al. Patients with inflammatory bowel disease may have a transforming growth factor-b-, interleukin (IL)-2 or IL-10-deficient state induced by intrinsic neutralizing antibodies. Clin. Exp. Immunol. 155(1), 65-71 (2009).
98. Street ME, De'Angelis G, Camacho- Hubner C et al. Relationships between serum IGF-1, IGFBP-2, interleukin-1b and interleukin-6 in inflammatory bowel disease. Horm. Res. 61(4), 159-164 (2004).
99. Mitsuyama K, Tomiyasu N, Takaki K et al. Interleukin-10 in the pathophysiology of inflammatory bowel disease: increased serum concentrations during the recovery phase. Mediators Inflamm. 2006(6), 26875 (2006).
100. Nancey S, Hamzaoui N, Moussata D, Graber I, Bienvenu J, Flourie B. Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity. Dig. Dis. Sci. 53(1), 242-247 (2008).
101. Ajdukovic J, Tonkic A, Salamunic I, Hozo I, Simunic M, Bonacin D. Interleukins IL-33 and IL-17/IL-17A in patients with ulcerative colitis. Hepatogastroenterology 57(104), 1442-1444 (2010).
102. Figueredo CM, Brito F, Barros FC et al. Expression of cytokines in the gingival crevicular fluid and serum from patients with inflammatory bowel disease and untreated chronic periodontitis. J. Periodontal Res. 46(1), 141-146 (2011).